Intelligence / Healthtech / New Clinical Trials / AstraZeneca
AstraZeneca
12 Nov 2026: Trial registered · A Phase III Study to Assess the Effect of FDC Laroprovstat/Rosuvastatin Compared With Laroprovstat, Rosuvastatin, and Placebo on LDL-C in LLT-naïve Patients. Recorded in the ClinicalTrials.gov (US National Library of Medicine).
- Posted
- 12 Nov 2026
- Title
- A Phase III Study to Assess the Effect of FDC Laroprovstat/Rosuvastatin Compared With Laroprovstat, Rosuvastatin, and Placebo on LDL-C in LLT-naïve Patients
- Conditions
- Hypercholesterolemia
- Phase
- Phase 3
- Study Type
- Interventional
- Status
- Not Yet Recruiting
- Countries
- China, Hong Kong, Malaysia, South Korea, Thailand, Vietnam
- Country
- China
- Reference
- NCT07930507
- Location
- China, Hong Kong, Malaysia
A new trial needs sites, patients, data capture, monitoring and regulatory partners for years.
- United States leads with 192 of 777, then China (171).
- 777 added in the 30 days to 18 Nov 2026.
Find the decision makers at AstraZeneca
AOS maps the buying committee, finds verified work emails and drafts outreach that cites this clinical signal, for your approval.
Across AOS Research
Other records for AstraZeneca in our registers.
More from China
New Clinical Trials
Source: ClinicalTrials.gov (US National Library of Medicine), data to 18 Nov 2026. Trials first posted in the window whose lead sponsor is a company, worldwide. Device and diagnostic studies usually have no phase. AOS shows what the public record says; it does not verify or endorse the company.